Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | RCEL | Common Stock | 14.9K | Jan 19, 2023 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | RCEL | Stock Options (Right to Buy) | Jan 19, 2023 | Common Stock | 9K | $4.26 | Direct | F2, F3, F4 | ||||||
holding | RCEL | Stock Options (Right to Buy) | Jan 19, 2023 | Common Stock | 5K | $4.26 | Direct | F2, F4, F5 | ||||||
holding | RCEL | Stock Options (Right to Buy) | Jan 19, 2023 | Common Stock | 5K | $6.38 | Direct | F2, F6, F7 | ||||||
holding | RCEL | Stock Options (Right to Buy) | Jan 19, 2023 | Common Stock | 5K | $39.58 | Direct | F2, F8, F9 | ||||||
holding | RCEL | Stock Options (Right to Buy) | Jan 19, 2023 | Common Stock | 30K | $21.93 | Direct | F10 | ||||||
holding | RCEL | Stock Options (Right to Buy) | Jan 19, 2023 | Common Stock | 2.3K | $20.21 | Direct | F11 | ||||||
holding | RCEL | Stock Options (Right to Buy) | Jan 19, 2023 | Common Stock | 1.65K | $18.21 | Direct | F12 | ||||||
holding | RCEL | Stock Options (Right to Buy) | Jan 19, 2023 | Common Stock | 7.05K | $4.97 | Direct | F13 |
Id | Content |
---|---|
F1 | Includes unvested Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. |
F2 | These Stock Options were originally exercisable for ordinary shares of Avita Medical, Ltd. ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise be exercisable. |
F3 | These Stock Options became exercisable upon the satisfaction of time-based and performance-based vesting criteria. |
F4 | The exercise price was converted from A$0.056, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (June 12, 2018). |
F5 | These Stock Options become exercisable in four equal annual installments beginning on June 12, 2019. |
F6 | These Stock Options become exercisable in four equal annual installments beginning on November 1, 2019. |
F7 | The exercise price was converted from A$0.089, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (November 1, 2018). |
F8 | These Stock Options become exercisable in four equal annual installments beginning on October 1, 2020. |
F9 | The exercise price was converted from A$0.590, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (October 1, 2019). |
F10 | These Stock Options become exercisable in four equal annual installments beginning on March 17, 2022. |
F11 | These Stock Options become exercisable in four equal annual installments beginning on July 6, 2022. |
F12 | These Stock Options become exercisable in four equal annual installments beginning on August 26, 2022. |
F13 | These Stock Options become exercisable in three equal annual installments beginning on August 20, 2023. |